4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 53 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,198,751 | -28.0% | 172,722 | +2.2% | 0.00% | -100.0% |
| Q2 2023 | $3,055,348 | +1.3% | 169,084 | -3.7% | 0.00% | 0.0% |
| Q1 2023 | $3,017,120 | -47.9% | 175,516 | -32.7% | 0.00% | 0.0% |
| Q4 2022 | $5,790,235 | +171.0% | 260,704 | -2.0% | 0.00% | – |
| Q3 2022 | $2,137,000 | +149.9% | 265,892 | +117.3% | 0.00% | – |
| Q2 2022 | $855,000 | -53.8% | 122,384 | 0.0% | 0.00% | – |
| Q1 2022 | $1,851,000 | -67.8% | 122,384 | -53.3% | 0.00% | -100.0% |
| Q4 2021 | $5,747,000 | +46.8% | 261,947 | +190.2% | 0.00% | 0.0% |
| Q1 2021 | $3,914,000 | -54.9% | 90,251 | -56.9% | 0.00% | -50.0% |
| Q4 2020 | $8,670,000 | – | 209,179 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 831,267 | $22,419,000 | 5.52% |
| Aquilo Capital Management, LLC | 1,099,944 | $29,665,000 | 5.39% |
| BVF INC/IL | 2,005,862 | $54,098,000 | 2.11% |
| Casdin Capital, LLC | 1,115,455 | $30,084,000 | 0.75% |
| Soleus Capital Management, L.P. | 120,900 | $3,261,000 | 0.51% |
| Eagle Health Investments LP | 57,090 | $1,540,000 | 0.49% |
| Centiva Capital, LP | 358,863 | $7,220,000 | 0.45% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $106,206,000 | 0.29% |
| ArrowMark Colorado Holdings LLC | 1,003,447 | $27,063,000 | 0.21% |
| Perceptive Advisors | 375,256 | $10,121,000 | 0.15% |